Economic burden of sickle cell disease in Brazil.

BACKGROUND: Sickle cell disease (SCD) may cause several impacts to patients and the whole society. About 4% of the population has the sickle cell trait in Brazil, and 60,000 to 100,000 have SCD. However, despite recognizing the significant burden of disease, little is known about SCD costs.
OBJECTIVE: To estimate SCD societal costs based on disease burden modelling, under Brazilian societal perspective.
METHODS: A disease burden model was built considering the societal perspective and a one-year time horizon, including direct medical and indirect costs (morbidity and mortality). The sum of life lost and disability years was considered to estimate disability-adjusted life years (DALYs). Data from a public database (DATASUS) and the prevalence obtained from literature or medical experts were used to define complications prevalence and duration. Costs were defined using data from the Brazilian public healthcare system table of procedures and medications (SIGTAP) and the human capital method.
RESULTS: Annual SCD cost was 413,639,180 USD. Indirect cost accounted for the majority of burden (70.1% of the total; 290,158,365 USD vs 123,480,816 USD). Standard of care and chronic complications were the main source of direct costs among adults, while acute conditions were the main source among children. Vaso-occlusive crisis represented the complication with the highest total cost per year in both populations, 11,400,410 USD among adults and 11,510,960 USD among children.
CONCLUSIONS: SCD management may impose an important economic burden on Brazilian society that may reach more than 400 million USD per year.

Introduction

Sickle cell disease (SCD) involves a group of inherited conditions in which both alleles for beta-globin are mutated and at least one is the mutation for beta-S-globin, with a quantitative predominance of hemoglobin S within the red blood cells. Depending on the mutations type, heterozygosis or homozygosis, the disease classification is sickle cell anemia (SCA; hemoglobin SS), hemoglobin SC or hemoglobin S/β-thalassaemia [1]. The disease is most commonly observed among sub-Saharan Africans; however, it is globally observed. Considering SCA frequency, it is estimated that 300,000 children are born globally with the disease per year. This number will reach 400,000 in 2050 [2].

In Brazil, a study has estimated that one in every six newborns have abnormal hemoglobins, encompassing all hemoglobinopathies [3]. Another study reported that 3.9% of the adults receiving treatment at hematology outpatient clinics have SCD [4]. Brazilian Ministry of Health estimates that about 4% of the population have the sickle cell trait and that homozygous or compound heterozygous disease is present among 60,000 to 100,000 people [5]. Furthermore, a mortality rate of 1.12/100,000 habitants is estimated [6]. Despite the efforts promoted by the Ministry of Health to propose national public policies, disparities in SCD patients’ care are still observed across country regions [7].

The SCD management may include the use of hydroxyurea, folic acid, blood transfusion, iron chelators, antibiotic therapies, vaccination, and hematopoietic stem cell transplantation [5, 8]. However, only hematopoietic stem cell transplantation has a curative intention for a few patients. Hydroxyurea and red blood cell transfusion are the major disease-modifying therapies. Despite treatment, patients still experience several systemic manifestations of SCD [8, 9].

Since SCD is a multisystem disorder, every organ in the body can be affected. Patients could present multiple complications such as acute chest syndrome, acute ischemic stroke, splenic sequestration, avascular necrosis, leg ulcerations, priapism, cholelithiasis, vaso-occlusion crisis (VOCs), and others [1, 10]. A Brazilian study has reported that only 4.63% of deaths among SCD patients are unrelated to the disease. The leading causes of death arre infection (29.18%) and acute chest syndrome (25.27%) [6]. Furthermore, patients with a higher number of VOCs in a year have an increased likelihood of experiencing other SCD-related complications and death [11]. Considering that SCD patients have higher morbidity and mortality, understanding the disease burden and the impact of several complications is important to support health policy-making decisions in the country [2]. In addition, the Brazilian public healthcare system has equity as one of its principles, which turns the disease burden into an impact on society [12].

The disease burden stimulated many interventions such as neonatal screening, bacterial prophylaxis, and comprehensive healthcare management [2]. In Brazil, the clinical protocol and therapeutic guidelines published by the Ministry of Health in 2018 propose similar disease management and screening [5].

Despite these initiatives and the increase in survival, mortality rates are still high in Brazil. Arduini et al. (2017) conducted a systematic review aiming to characterize mortality by SCD in Brazil in respect to the frequency, death rate or mortality coefficient, age, and causes. Mortality rates ranged from 0.115 to 0.54 per 100.000 individuals, depending on the studied population, region, and other variables. This data highlights the scarcity of information about SCD-related deaths in Brazil [13]. In addition, Brazilian SCD patients’ life expectancy is about 20 years lower than the observed for the whole country [6].

Beyond the mortality rates and impact on patients’ life, little is known about SCD costs. Most of the available studies reports only costs among hospitalized patients [14-17]. Kauf et al. (2009) reported an average total cost of care per patient-month of USD 1,946 [18]. Shah and coworkers (2020) reported mean annual cost per patient of USD 1,204 and highlighted the severe impact of VOCs on resource utilization [19]. However, only direct medical costs were included [18, 19]. In Brazil, Lobo and colleagues (2022) reported emergency visits and hospitalizations total costs higher than USD 500,000 [20]. Nevertheless, only a single study, conducted in a single center, reporting direct costs is available to date.

Considering the lack of knowledge on the SCD burden, this study aims to estimate SCD societal costs based on disease burden modelling, under a Brazilian societal perspective.

Methods

A disease burden model was built considering the societal perspective and a one-year time horizon, including direct medical costs and indirect costs (morbidity and mortality). Although a time horizon of one year was used for years lost to disability (YLD) estimation, years of life lost (YLL) calculation used the life expectancy approach. The indirect cost estimates productivity lost due to early death.

The analysis followed the methodology proposed by Larg & Moss (2011) for a cost-of-illness evaluation. The study should include an analytical framework (study perspective and motivation, epidemiologic approach, and a well-specified question), an adequate methods definition and data regarding productivity loss and resource use (quantification, healthcare resource, and productivity loss values definition and the inclusion of intangible costs) as well as adequate data analysis and reporting (presence of a range of estimates, identification of main uncertainties, sensitivity analysis, adequate documentation and justification given for cost components, data and sources, assumptions and methods, identification of main study limitations and level of results detail to answer study questions) [21].

DALY calculation was aided by WHO’s DALY calculator tool following the methodology depicted at WHO methods and data sources for global burden of disease estimates 2000–2011 [22, 23]. Age-weighting and the discount rate were not used as the World Health Organization recommended. The definition of DALY is given by Eq 1 [24].

YLL is estimated by Eq 2, where Nd(a) is the number of deaths by SCD and L(a) is the life expectancy at age a.

YLD is given by Eq 2, through the prevalence method, where Np(a) is the number of SCD’s patients at age a, p(c, age group) is the prevalence of complication c (can be chronic or acute) by age group (children or adults), AER(c) is the annualized event rate of c, DW(c) is disability weight of complication c, and d(c) the duration of the complication c from the onset until remission or death [23].

Nd(a) is calculated by applying the SCD mortality rate to the prevalent population. However, the raw number from the official registry was not used as death by SCD is known to be underreported in Brazil. Instead, the resulting total number of deaths per year was distributed through age according to the ICD-10 code D57 in the Brazilian official death registry. Thereby, the death proportion by age and the estimated total number of deaths per year were used.

Life expectancy was extracted from the National Mortality Table published by the Brazilian Institute of Geography and Statistics (IBGE) [25] and disability weights (DW) from the Global Burden of Disease 2010 (GBD 2010) and the Institute for Health Metrics and Evaluation (IHME) [26]. When DW were not found on the references mentioned above, economic evaluation literature was searched for utility values used as proxies to DW. Complications’ prevalence was extracted from the literature, when available, or expert medical opinion. Annualized event rate (AER) and complication duration were calculated from DATASUS, an open database that centralizes claims from all the Brazilian public healthcare system.

Data analysis of DATASUS comprised the period from January/2008 to December/2018, considering all hospitalizations registered with ICD-10 D57 (SCD). Annualized hospitalization rates were estimated by the ratio between complications count and the total number of patients-year of DATASUS.

The average event duration was based on inpatient data related to more severe cases. Therefore, the burden of some events may be overestimated. This limitation could not be avoided as outpatient event duration data is unavailable and must be noted as a limitation of the present study.

Eq 1. DALY definition.

Eq 2. YLL and YLD definition.

Direct medical costs were estimated using a bottom-up strategy. A literature review identified SCD treatment and main complications. Their costing was defined through the micro-costing method, broadly defined in two steps: definition of health resource use and subsequent costing [27]. The first was extracted from published guidelines, while the latter was set from the Brazilian public healthcare system table of procedures and medications (SIGTAP). Due to many uncertainties, direct non-medical costs were not included since they can hardly be evaluated. Nevertheless, this is a conservative approach since costs, such as transportation for medical appointments, may impose an important burden, as the few reference centers are usually far from patients’ residences.

Indirect medical costs were based on the average annual income in Brazil (7,416.45 USD) published by the IBGE in 2020 [28].

The total disease burden was calculated by Eq 3.

Eq 3. Total disease burden.

Where EMC(c) is the event management cost (direct costs only) of complication c and TC is SCD standard management cost (hydroxyurea, folic acid, blood transfusion, iron chelators, hematopoietic stem cell transplantation–HSCT, antibiotic therapy and vaccination) by age group.

A literature review was performed until October 2019 using MEDLINE databases via Pubmed and Latin American and Caribbean Health Sciences Literature (LILACS). Data from a multinational study were also used when information was not available in national literature [29]. An expert panel was further conducted, on June 17, 2020, on an online platform. Five Brazilian experts were responsible for validating all data retrieved on the literature review and provided inputs on those without published information.

Values were reported in US dollars (USD) with 1 USD = 3.88 Brazilian Reais (BRL).

Parameters’ uncertainty was evaluated under a deterministic sensitivity analysis. They were varied according to their respective 95% CI, when available. Otherwise, a standard variation of ±20% was applied. The results of the analysis were expressed as a tornado diagram.

Results

Epidemiology

Given the information scarcity and that disease prevalence in Brazil varies in the available literature, the prevalence of 24.0 cases per 100,000 inhabitants was defined, as proposed by medical experts (ME). According to the IBGE population projection, this prevalence results in approximately 50,000 patients with the disease in 2018, segmented by age [30]. A mortality rate of 2.68/1,000,000 inhabitants was assumed, as the weighted average for men and women resulted in 558 patients lost to the disease in the same year [31]. The estimative is that the SCD mortality rate is underreported because the primary diagnosis is omitted and considered only the immediate death cause, as an acute stroke or acute chest syndrome. Total deaths were age-segmented according to mortality data from the Mortality Information System (Fig 1) [32].

Fig 1

Estimated number of deaths per age group among SCD patients.

Disease complications

Table 1 shows complications’ prevalence, DW extracted from literature, mean hospitalization duration of acute events, and annual incidence rate, stratified by adults and children. VOC was the most frequently observed acute complication with the longer length of hospital stay. However, the most significant disability was related to stroke. The literature reports the highest frequency for chronic calculous cholecystitis and chronic kidney disease (without failure) as chronic conditions among adults and children, respectively.

Table 1

Morbidity parameters (acute and chronic complications).

	Adults		Children		Annualized hospitalization rate	Mean duration (days)	Disability Weight
	%	Reference	%	Reference			Number	Reference
Acute complications
Vaso-occlusion	75.0	[33]	59.5	[34]	5.30	15	0.01	[35]
Hand-Foot syndrome	0.0	ME	25.0	ME	5.30	15	0.01	[35]
Infections	32.0	ME	50.0	ME	0.12	5	0.21	[36]
Splenic sequestration	2.0	ME	34.9	[37]	0.09	6	0.19	[36]
Liver sequestration	0.1	ME	2.0	ME	0.11	6	0.18	[35]
Cholelithiasis	35.4		27.0		0.09	5	0.11	[35]
Deep venous thrombosis	10.0	[38]	2.0	ME	0.12	10	0.18	[39]
Acute chest syndrome	30.0	ME	55.0	[34]	0.11	7	0.21	[36]
Priapism	26.0	[34]	12.9	[34]	0.14	5	0.00	Assumption
Stroke	14.5	[34]	10.0	ME	0.12	9	0.43	[35]
Osteonecrosis	13.5	[34]	1.6	[34]	0.12	4	0.24	[40]
Chronic complications
Chronic calculous cholecystitis	62.0	ME	18.9	ME	-	-	-	-
Cardiac complications	15.8	[34]	2.6	[34]	-	-	-	-
Chronic kidney disease (failure)	4.0	ME	0.1	ME	-	-	-	-
Chronic kidney disease (without failure)	38.9	[41]	20.0	ME	-	-	-	-
Chronic liver disease	17.0	ME	8.1	ME	-	-	-	-
Leg ulcers	17.8	[42]	0.7	[42]	-	-	-	-
Osteoporosis	24.5	[43]	10.0	ME	-	-	-	-
Pulmonary hypertension	10.0	[38]	1.0	ME	-	-	-	-
Recurrent priapism	15.0	ME	6.9	[42]	-	-	-	-
Retinopathy	37.2	[44]	5.0	ME	-	-	-	-

ME: Medical Expert.

Direct medical costs

Table 2 shows the standard of care costs per patient. Annual costs attributed to chronic and acute complications are shown in Table 3. SCD related cost was composed by the summation of the standard of care and chronic complications’ costs. Acute complications and HSCT costs were calculated per event, not as chronic costs. The standard of care average costs assumed were 1,835.92 USD and 987.21 USD, while for chronic complications were 769.30 USD and 116.62 USD, for adults and children, respectively. Acute complications costs were estimated as 595.68 USD and 703.71 USD for adults and children, respectively. Despite its high cost per event, HSCT-related costs were estimated as 60.94 USD and 39.61 USD for adults and children, respectively. This apparent inconsistency is directly related to the low incidence of the procedure.

Table 2

Standard of care cost.

	Adults		Children		Cost per year adults (USD)	Cost per year children (USD)	Cost reference
	%	Reference	%	Reference
Medical visit	100	ME	100	ME	7.73	10.31	SIGTAP
Hydroyurea	50.0	ME	29.0	[42]	282.22	98.21	SIGTAP
Folic acid	96.5	ME	97.3	ME	1.36	1.37	BPS (01/2020)
Blood transfusion	11.0	ASH 2017	10.6	[42]	192.03	185.05	Estimated
Iron chelators	15.0	ME	12.0	[42]	1352.58	529.76	BPS (06/2020)
Antibiotic prophylaxis	0.0	ME	15.0	ME	-	79.46	BPS (01/2020)
Vaccine	0.0	ME	87.4	ME	-	83.05*	PAHO (2020)
Total cost per patient (BRL)	-		-		1,835.92	987.21	-

BPS: Banco de preços em saúde; USD: American dollars; ME: Medical Expert; PAHO: Pan-American Health Organization; SIGTAP: Brazilian public healthcare system table of procedures and medications.

* Pneumococcal polysaccharide vaccine 23-valent / 10-valent pneumococcal conjugate vaccine (PCV-10).

Table 3

Chronic and acute complications health-state costs.

	Adults		Children		Cost per year/event (USD)
	%	Reference	%	Reference
Acute complications
Vaso-occlusion	75.0	[33]	59.5	[34]	130.36
Hand-foot syndrome	0.0	ME	25.0	ME	130.36
Infections	32.0	ME	50.0	ME	993.43
Splenic sequestration	2.0	ME	34.9	[37]	533.58
Liver sequestration	0.1	ME	2.0	ME	314.57
Cholelithiasis	35.4	[42]	27.0	[45]	164.31
Deep venous thrombosis	10.0	[38]	2.0	ME	238.95
Acute thoracic syndrome	30.0	ME	55.0	[34]	529.44
Priapism	26.0	[34]	12.9	[34]	115.70
Stroke	14.5	[34]	10.0	ME	434.07
Osteonecrosis	13.5	[34]	1.6	[34]	110.39
Health state cost (USD)	595.68		703.71		-
Chronic complications
Chronic calculous cholecystitis	62.0	SWAY	18,9	SWAY	147.19
Cardiac complications	15.8	[34]	2,6	[34]	254.05
Chronic kidney disease (failure)	4.0	ME	0,1	ME	8,398.20
Chronic kidney disease (without failure)	38.9	[41]	20,0	ME	113.54
Chronic liver disease	17.0	ME	8,1	ME	103.65
Leg ulcers	17.8	[42]	0,7	[42]	611.28
Osteoporosis	24.5	[43]	10,0	ME	157.66
Pulmonary hypertension	10.0	[38]	1,0	ME	267.40
Recurrent priapism	15.0	ME	6,9	[42]	227.30
Retinopathy	37.2	[44]	5,0	ME	85.80
Health-state cost (USD)	769.30		116.62		-
HSCT	0.2	ME	0.1	DATASUS	28,364.31
Follow-up	100	ME	100	ME	2,105.50
Health-state cost (USD)	60.94		39.61		-

USD: American dollars; HSCT: hematopoietic stem cell transplantation; ME: Medical Expert; SWAY: Sickle Cell World Assessment Survey.

Economic burden

Annual SCD cost in Brazil was approximately 414 million USD or 1.6 billion BRL per year, of which 290 million USD (1.1 billion BRL) and 123 million USD (479 million BRL) were related to indirect and direct costs, respectively. Approximately 41,000 DALYs were lost in 2018, 27,000 due to death, and 14,000 due to disability (Table 4).

Table 4

Disease burden.

Outcome	Adults	Children
Direct medical costs (USD)
Standard of care	40,390,236	27,642,008
Chronic complications	16,924,650	3,265,344
Chronic calculous cholecystitis	2,007,717	778,947
Chronic kidney disease (without failure)	971,686	635,831
Retinopathy	702,177	120,118
Osteoporosis	849,807	441,458
Leg ulcers	2,393,783	119,811
Chronic liver disease	387,639	235,071
Cardiac complications	883,063	184,945
Recurrent priapism	750,086	439,141
Pulmonary hypertension	588,278	74,872
Chronic kidney disease (failure)	7,390,414	235,150
Acute complications	13,105,040	19,703,765
Vaso-occlusion	11,400,410	11,510,960
Hand-foot syndrome	0	4,836,538
Infections	824,297	1,639,227
Splenic sequestration	21,338	473,897
Liver sequestration	738	18,790
Cholelithiasis	120,495	116,968
Deep venous thrombosis	63,408	16,140
Acute thoracic syndrome	378,095	882,221
Priapism	92,231	58,241
Stroke	165,094	144,910
Osteonecrosis	38,933	5,873
HSCT	1,340,671	1,109,101
Total cost	123,480,816
Indirect costs
DALY	22,691	18,044
YLD	5,984	7,627
YLL	16,706	10,417
Indirect costs (USD)	168,284,496	121,873,869
Total cost (USD)	290,158,365
Direct medical costs + indirect costs
Total cost (USD)	413,639,180

USD: American dollars; DALY: Disability-adjusted life years; HSCT: hematopoietic stem cell transplantation; YLD: Years lived with disability; YLL: Years of life lost.

Deterministic sensitivity analysis

Parameters that most influenced the model results were: SCD prevalence, annual income, VOC annualized rate, and SCD base utility. The first three parameters increment resulted in an increased disease burden. At the same time, the SCD base utility improvement reduced the disease burden. This behavior is expected once the improvement of SCD base utility results in reduced patient absenteeism. Fig 2 shows the deterministic sensitivity analysis complete results. Values and ranges considered for each parameter are in the S1 File.

Fig 2

Tornado diagram assessing each parameter role in model results.

Discussion

This study aimed to estimate the SCD burden, considering the Brazilian societal perspective. To the best of the authors’ knowledge, this is the first study to assess Brazil’s SCD burden and add important knowledge to improve disease management and decision-making.

Economic burden related to several hematologic conditions were previously conducted in Brazil [20, 46–50]. However, there are no studies using similar methods to estimate burden of illness in the country to date.

Data related to disease epidemiology were collected to allow SCD burden estimation in Brazil. Data available at the information system was analyzed stratified by age groups regarding mortality. It was possible to notice that mortality rates are still higher in young ages, such as children. This pattern is quite different from those observed in developed countries. Payne et al. (2020) assessed the trends in SCD-related mortality among black Americans considering 1979–2017 period and reported a decline in death rates among children and an increase among adults, with the median age at death increasing from 28 to 43 years [51]. Thus, it is possible to highlight that the disease burden may still be higher in developing countries, such as Brazil, considering the delay in disease management. High mortality rates were also reported in other studies. Cançado et al. (2021) reported that SCD is related to a reduction of approximately 37 years on median age at death, compared to the general population, which was also observed when data were stratified by age [52].

In the present study, the total cost related to SCD in a year was estimated at 413,639,180 USD, considering both adults and children. Most of this burden was related to indirect costs, representing 70.2% of the total amount. Previous studies worldwide assessing SCD burden reported, in the majority, data considering only those related to direct medical costs [53-61]. Naik et al. (2019) reported a total direct annual cost that ranged from 1 million USD to 3 million USD and an average annual indirect cost of 1,293 USD in a systematic review aiming to synthesize worldwide SCD economic burden. The lack of detailed information on Naik et al. (2019) does not allow us to understand the reason for the differences observed [62]. However, in another review that aimed to estimate the SCD economic burden in the United States, the authors highlighted the need for studies considering direct and indirect costs to characterize the full burden of disease [61]. Thus, despite the differences among estimates shown in the present study and those in the analysis from Naik et al. (2019), the impact of indirect costs on total SCD burden still needs to be better understood in further studies [62].

Still, regarding the indirect disease burden, the estimated total DALY loss in 2018 was 22,755 and 18,085 among adults and children, respectively. Considering both premature death and the years lived with disability, the disease substantially impacts the whole Brazilian society. Similarly, Rezaei et al. (2015) assessed DALYs estimations due to hemoglobinopathies (thalassemia, SCD, and G6PD-D) in Iran by sex and age in 1990, 2005, and 2010. Using data from Global Disease Burden, the study reported total DALY among SCD patients of 51,129 and 30,501 in 1990 and 2010, respectively, showing a decreasing trend across the years. However, in contrast to our findings, DALYs lost per adult were lower than those lost per children (369 among children ≤14 years vs. 88 among adults ≥15 years, in 1990; 204 among children ≤14 years vs. 66 among adults ≥15 years, in 2010) [63].

The SCD direct medical costs were estimated at 123,480,816 USD for 2018 in Brazil. Standard of care was the main driver of direct costs, followed by acute complications in both populations. However, among children, acute complications costs were about six times higher than those observed for chronic ones, while among adults, values were closer. This difference is influenced by the frequency of such complications since children have a higher frequency of acute conditions and adults the chronic ones [34, 42].

Considering total costs related to complications’ management in a year, VOC represents the most expensive acute condition in both populations. About 87% of all acute complications’ costs were related to VOCs among adults.

The condition’s occurrence may explain this finding since VOC was the most frequently observed complication among children (59.5%) and adults (75.0%). In addition, the condition was responsible for the highest annualized hospitalization rate (5.30 per year) and length of hospital stay (mean duration of 15 days). Previous studies in Brazil reported that acute painful episodes are the leading cause of hospitalization among SCD patients, which may reach about 70% of the cases [64, 65].

VOCs disrupt blood circulation, which drives acute and chronic pain beyond the damage to key organs such as the liver, brain, lungs, and kidneys [66]. In addition, the condition is directly associated with mortality, with a risk of death 5.5 times higher among patients with ≥3 VOCs per year compared to those with <1 episode [11]. In the present analysis, the estimated cost per event was 130.36 USD. Despite the low cost, SCD patients may experience ≥ 6 VOCs per year, which explains the amount spent in a year (11,400,410 USD among adults and 11,510,960 USD among children) [67]. The burden related to VOC may still be higher since some issues like the hospital beds occupation were not considered in this analysis. These data highlight the importance of strategies to control disease to avoid VOCs occurrence. Furthermore, patients with uncontrolled disease seems to have a higher resource utilization and costs [68].

This study was designed to follow the checklist proposed by Larg & Moss (2011), and most of the items were addressed. However, it was impossible to control confounders and provide the required level of detail of resource use and productivity loss. Data were extracted from literature and reports from key-opinion leaders, which may not represent the Brazilian scenario in some cases. Still, it was the available source when the study was conducted. A deterministic sensitivity analysis was conducted to estimate the influence of the model parameters on the modeled results to address some of these limitations. It is important to note that parameters were varied according to their respective 95% CI, when available, or using a standard variation of ±20%, considered wide enough to evaluate the model behavior under uncertainty [21]. The results highlight the model’s sensitivity, especially to SCD prevalence, which is almost natural as the increase in the number of cases will inevitably lead to a higher burden of the disease. The same will happen to an increase in annual income as the magnitude of the results is directly related to indirect costs, income dependent. Finally, an increase in SCD base utility will reduce DW (better quality of life), reducing the disease burden. Somehow, deterministic sensitivity analysis results give rise to the necessity of SCD prevalence studies, which can refine future disease burden analysis.

Thus, although the study adds valuable knowledge, these limitations need to be highlighted. In addition, the absence of direct non-medical costs may translate to an underestimation of disease burden since the availability of reference centers in a few places may represent the need for frequent transportation for medical assistance, change of residence place, and others. However, in contrast, mortality quoted comes from a specialist hospital and may translate into a more severe population. Considering that SCD patients who are well may not need such resources, further analysis addressing this limitation is needed. Finally, the hospitalization rate was estimated through data available from DATASUS. Although it is a national source of information, only those related to public assistance are reported, and it is usually not registered as a condition related to SCD, underestimating the occurrence of the outcome.

Conclusion

The present analysis showed that SCD patients might generate an economic burden for the Brazilian society of approximately 400 million USD per year. The indirect burden is responsible for most of this cost; however, disease complications play an important role in direct medical costs. Thus, the present data highlights the importance of investment in disease control to reduce its impact on patients and society.

(DOCX)

Click here for additional data file.

11 Feb 2022

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Mohamed A Yassin, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for stating the following financial disclosure:

"Novartis Brazil funded this study."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Please include a separate caption for each figure in your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: PONE-D-22-01357Economic burden of sickle cell disease in Brazil

The authors use publicly available data to determine the economic burden to the society of providing medical care for people living with SCD (PLWSCD). They include indirect costs, an important component of total economic cost.

Abstract

The English can be improved. For example, “Sickle cell disease (SCD) may cause several impacts to patients and the whole society.”

The use of the BRL is difficult for the international audience. Consider using a commonly understood currency equivalent such as the USD or GBP, or at least stating whet he exchange rate was in the captioned year.

Introduction

The English can be improved. While it is difficult to give specific examples, the manuscript would benefit from thorough review by a proofreader. Some examples include “composed heterozygous disease”. “Furthermore, a mortality rate of 1.12/100,000 habitants is estimated”, “Only hematopoietic stem cell transplantation has a curative intention, however, for few patients.”, “disparities on SCD patients’ care”, “It was possible to notice that mortality rates are still higher in young ages, such as children.”.

The mortality quoted comes from a specialist hospital “Furthermore, a mortality rate of 1.12/100,000 habitants is estimated [6]”. It has been shown that this is a biased (more severe) population and that ideally cohorts assembled at newborn screening are the best approach. Given that “In Brazilian context, direct non-medical costs, such as transport for medical appointments, may impose important burden since disease reference sites are located in few places.”, PLWSCD who are well may not make the trip. This limitation should be acknowledged.

The authors say that “Considering the disease burden, many interventions such as neonatal screening, bacterial prophylaxis and a comprehensive healthcare management have been established [2]”, quoting an international commentary and not speaking to how often these interventions are applied in Brazil.

Similarly, the cost of care quoted was from Florida. “Kauf et al. (2009) reported an average total cost of care per patient-month of USD1,946, however only direct medical costs were included [16].”

The population of Brazil is approximately 212.6 million. The upper limit of the estimated SCD population is 100,000. This gives a maximum estimate of prevalence of 0.5% of the total population having SCD. The fact that people living with SCD (PLSCD) have related deaths and morbidity does not clearly show that “As a consequence, SCD patients have greater morbidity and mortality which could impact the whole society”.

There should be a reference at the end of this critical sentence “The analysis followed the methodology proposed by Larg & Moss (2011) for a cost-of-illness evaluation”.

Agree that reference is missing “Direct medical costs were estimated using a bottom-up strategy with the identification of the main health states related to SCD (Error! Reference source not found.)”.

There are references published before October 2019 which have been omitted. Arduini (2017) looks at several studies regarding SCD mortality in Brazil including one by Ramos (2015) from which he quotes an estimate of a mortality coefficient of 0.54 per 100,000 individuals.

Figures 1 and 2 are unhelpful. It is not clear what they are saying.

Methods

Given that it is now 2022, the halting of the literature review more than two years ago is unacceptable. There have been significant publications since then which must be mentioned in discussing how use of the different estimates may have affected the final outcomes. “Literature review was performed until October 2019”. Santo et al (2020) estimate annual mortality rates at approximately 2.65 and 2.7 per million for men and women respectively. This is very different from the 1.1% used here and would impact estimates significantly. Sensitivity analyses for these possibilities would be necessary. The YLL would be significantly lower using these estimates.

What does this sentence mean? “Disability attributed to chronic complications was incorporated from the sickle cell anemia DW”.

Results

It is not clear where the following sentence comes from. Is it a result arising from this research? “A prevalence of 24.0 cases per 100,000 inhabitants was considered, resulting in approximately 50,000 patients with the disease in 2018, segmented by age according to the IBGE population projection [24].”

Similarly, is the calculation all done on the opinion of the medical expert? Most of the calculated costs come from indirect costs which are based on these premises.

“Considering the scarcity of information and that disease prevalence in Brazil varies in the available literature, data was defined as an assumption proposed by ME. A disease specific mortality rate of 1.12% was assumed, resulting in 560 patients lost to the disease in the same year [6].

The quoted study is not the only publication on SCD mortality in Brazil.

Table1. For acute complications, please clarify whether the presented %s are for the captioned year. Did 26% of all PLWSCD, and therefore approximately 52% of all men have priapism annually? Did 35.4% of PLWSCD have cholelithiasis annually;14.4% stroke, 32% infections (not including ACS)?

The opinions of medical experts can be influenced by their type of practice. Those in secondary or tertiary care may not see the asymptomatic persons. An example is proliferative sickle retinopathy. The reference (17). The estimate is taken from a single, cross-sectional study and ME. The estimate is much higher than that in a cohort study.

Is Figure 3 Are the deaths shown from SCD or the general population?

Are the YLL based on those who died only in the year under review?

More details are needed on how disability was assigned. I do not understand how the DW were calculated. The DW do not make intuitive sense to me. Stroke has DW of 0.08, but this acute episode has chronic disability associated. ACS which usually has no disability after the episode has a DW of 0.33.

How is the indirect cost calculated? In the last part of Table 4 (see below), the direct cost is $479,105,564. Is the DALY not the source of the indirect costs? By what calculation is the DALY 22,755 transformed to the indirect cost 654,790,110

Figure 4. This needs a proper title stating what Tornado diagram depicts.

What does SCD prevalence represent in terms of costs in the Tornado diagram?

Discussion

The high death rate among children is surprising, given that there is newborn screening, vaccines and prophylactic antibiotics. In another developing country, Jamaica, the mortality in children has fallen dramatically with these few, inexpensive interventions. More explanation is needed, such as the causes of death, given that these interventions are available in Brazil and hydroxyurea use (50%,29%) is relatively high for non non-developed country.

Are there publications from Brazil about economic burden of other diseases? This would aid in putting these results into context.

The other estimates of mortality rates should be discussed.

Reviewer #2: In this article, Carolina Bueno and colleagues estimate the monetary burden of Sickle Cell Disease (SCD) in Brazil and its effect and burden on the overall Brazilian Health care. The authors build a model using a one-year time horizon and considering direct medical costs and also indirect costs related to morbidity and mortality. The study concluded that burden for SCD care is at 1.6 billion Brazilian reals (approximately $300 million) pear year. The presented data also point to early childhood mortality, not seen in US, for example, and vaso-occlusive crises as the most frequent complication of SCD. Overall this is an interesting study, which is the first to estimate the burden of SCD in Brazil. The study provides a wealth of useful data and will be helpful for future public policy making decisions in Brazil. One major drawback is that the model is not well described (see detailed comments below). Also the authors need to fix numerous minor errors and provide additional citations and expand the discussion.

Major critiques:

1. Please provide more clear description of the model.

2. Please, provide more information about direct medical cost estimation. What is bottom-up strategy? Micro-costing method? Are there reference papers describing this methodology and strategy?

3. Figure 3 needs to have axis labels. It is unclear if this graph displays the estimated number of deaths per age group. Were these values per year or for the whole study, since data analysis was performed from 2008 to 2018? Please, clarify this in the text and also in the figure legend.

4. Authors should be more specific regarding which criteria and how medical experts validated complicated estimates.

5. Discussion, paragraph 9: you can expand the discussion and add references regarding deterministic sensitivity analysis and the influence of SCD prevalence, annual income and SCD base utility in disease burden.

Minor changes:

1. Page numbers need to be added.

2. Introduction, lane 5: “haemoglobin SS” – please change to “hemoglobin SS”. Also change throughout the manuscript.

3. Introduction, lane 7: “it is globally observed due to population migration.” – Slave trade is not exactly population migration, I suggest rephrasing it to clarify.

4. Introduction, lane 8: you may consider abbreviating sickle cell anemia as SCA.

5. Page 11, second paragraph: most of the available studies report only costs among hospitalized patients. However, Shah and coworkers (2020) reported the impact of vaso-occlusive crises in disease burden in non-hospitalized patients. Saraf and coworkers (2020) also demonstrated the cost impact of disease in a more specific SCD population. These manuscripts might be interesting to add to the discussion.

6. Tables 1, 2 and 3: References do not specify if they refer to children or adults. Please, clarify.

7. Table 3, please identify the acronym “SWAY”.

8. Page 12: “the main health states related to SCD (Error! Reference source not found.)” – please correct references.

9. Page 14, lane 6 “ data was defined” - “ data were defined.

10. Page 20, lane 25 “ estimated total DALY lost in 2018” should be “estimated total DALY loss in 2018”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

20 May 2022

The response to reviewers letter is attached in the new documents with all the answers required by the reviewers.

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

26 May 2022

Economic burden of sickle cell disease in Brazil

PONE-D-22-01357R1

Dear Dr.Carolina,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mohamed A Yassin, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The manuscript can be published in its current form

Reviewers' comments:

2 Jun 2022

PONE-D-22-01357R1

Economic burden of sickle cell disease in Brazil.

Dear Dr. Bueno:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Mohamed A Yassin

Academic Editor

PLOS ONE